It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The primary goal of this study was to evaluate the major roles of health-related quality of life (HRQOL) in a 5-year lung cancer survival prediction model using machine learning techniques (MLTs). The predictive performances of the models were compared with data from 809 survivors who underwent lung cancer surgery. Each of the modeling technique was applied to two feature sets: feature set 1 included clinical and sociodemographic variables, and feature set 2 added HRQOL factors to the variables from feature set 1. One of each developed prediction model was trained with the decision tree (DT), logistic regression (LR), bagging, random forest (RF), and adaptive boosting (AdaBoost) methods, and then, the best algorithm for modeling was determined. The models’ performances were compared using fivefold cross-validation. For feature set 1, there were no significant differences in model accuracies (ranging from 0.647 to 0.713). Among the models in feature set 2, the AdaBoost and RF models outperformed the other prognostic models [area under the curve (AUC) = 0.850, 0.898, 0.981, 0.966, and 0.949 for the DT, LR, bagging, RF and AdaBoost models, respectively] in the test set. Overall, 5-year disease-free lung cancer survival prediction models with MLTs that included HRQOL as well as clinical variables improved predictive performance.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Seoul National University College of Medicine, Department of Biomedical Science, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
2 National Cancer Center, National Cancer Control Institute, Goyang, Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810)
3 Seoul National University College of Medicine, Department of Biomedical Informatics, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
4 National Cancer Center, Center for Lung Cancer, Goyang, Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810)
5 Samsung Comprehensive Cancer Center, Samsung Medical Center, Lung and Esophageal Cancer Center, Seoul, Korea (GRID:grid.414964.a) (ISNI:0000 0001 0640 5613)
6 Seoul National University College of Medicine, Department of Biomedical Science, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University College of Medicine, Department of Biomedical Informatics, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University College of Medicine, Department of Family Medicine, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)